[Acute Myocardial Infarction and Purpuric Drug Eruption Caused by Erlotinib Combined with Cabozantinib:Report of One Case]

Tao Li; Li Jing Jia; Juan Zhang; Yi Hu

doi:10.3881/j.issn.1000-503X.10652

[Acute Myocardial Infarction and Purpuric Drug Eruption Caused by Erlotinib Combined with Cabozantinib:Report of One Case]

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019 Apr 28;41(2):278-282. doi: 10.3881/j.issn.1000-503X.10652.

[Article in Chinese]

Authors

Tao Li^{1

2}, Li Jing Jia³, Juan Zhang¹, Yi Hu¹

Affiliations

¹ Department of Oncology,the First Medical Center,Chinese PLA General Hospital,Chinese PLA Key Laboratory of Oncology, Ministry of Education Key Laboratory for Tumor-targeting Therapy and Antibody Drugs,Beijing 100853,China.
² Graduate School of Chinese PLA General Hospital,Medical School of Chinese PLA,Beijing 100853,China.
³ Department of Emergency,the First Medical Center,Chinese PLA General Hospital,Beijing 100853,China.

PMID: 31060687
DOI: 10.3881/j.issn.1000-503X.10652

Abstract

Multi-target anticancer drugs have a more comprehensive and extensive range of action,and there is an uncertain risk in the combination of two drugs.A case of acute toxicity induced by erlotinib combined with cabozantinib is reported in this article.

Publication types

Case Reports

MeSH terms

Anilides / adverse effects*
Drug Eruptions / etiology*
Drug Therapy, Combination / adverse effects
Erlotinib Hydrochloride / adverse effects*
Humans
Myocardial Infarction / chemically induced*
Pyridines / adverse effects*

Substances

Anilides
Pyridines
cabozantinib
Erlotinib Hydrochloride